Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 12/20 | 0.80 |
| ▸ | FGFR3 | P22607 | 9/20 | 0.68 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.55 |
| ▸ | JAK2 | O60674 | 2/20 | 0.55 |
| ▸ | ABL1 | P00519 | 2/20 | 0.55 |
| ▸ | INSR | P06213 | 2/20 | 0.55 |
| ▸ | FYN | P06241 | 2/20 | 0.55 |
| ▸ | YES1 | P07947 | 2/20 | 0.55 |
| ▸ | LYN | P07948 | 2/20 | 0.55 |
| ▸ | RET | P07949 | 2/20 | 0.55 |
| ▸ | MET | P08581 | 2/20 | 0.55 |
| ▸ | ROS1 | P08922 | 2/20 | 0.55 |
| ▸ | KIT | P10721 | 2/20 | 0.55 |
| ▸ | SRC | P12931 | 2/20 | 0.55 |
| ▸ | BRAF | P15056 | 2/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.55 |
| ▸ | FLT1 | P17948 | 2/20 | 0.55 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.55 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.55 |
| ▸ | TYK2 | P29597 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19224079 | 0.91 | LCK (0.81) | LCKFGFR3FGFR1JAK2ABL1 | |
| SCHEMBL374238 | 0.88 | FGFR3 (0.72) | LCKFGFR3FGFR1JAK2ABL1 | |
| SCHEMBL17537388 | 0.88 | LCK (0.76) | LCKFGFR3FGFR1JAK2ABL1 | |
| SCHEMBL17537387 | 0.87 | LCK (0.75) | LCKFGFR3FGFR1JAK2ABL1 | |
| SCHEMBL17537436 | 0.81 | LCK (1.00) | LCKFGFR3FGFR1JAK2ABL1 | |
| SCHEMBL17537389 | 0.81 | LCK (0.68) | LCKFGFR3JAK2ABL1FYN | |
| SCHEMBL374547 | 0.81 | FGFR3 (1.00) | LCKFGFR3FGFR1JAK2ABL1 | |
| SCHEMBL19224081 | 0.81 | LCK (0.68) | LCKFGFR3FGFR1JAK2ABL1 | |
| SCHEMBL374214 | 0.81 | FGFR3 (1.00) | LCKFGFR3FGFR1JAK2ABL1 | |
| SCHEMBL23771703 | 0.80 | FGFR3 (0.85) | LCKFGFR3FGFR1JAK2ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220305016-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS | THE GENERAL HOSPITAL CORPORATION (US) | 2022-09-29 | — | — | US | disclosed |
| US-11241435-B2 | Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis | THE GENERAL HOSPITAL CORPORATION (US) | 2022-02-08 | — | — | US | disclosed |
| US-20200338087-A9 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-20200179387-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS | THE GENERAL HOSPITAL CORPORATION (US) | 2020-06-11 | — | — | US | disclosed |
| US-20190343842-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-11-14 | — | — | US | disclosed |
| EP-3536323-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | Dana Farber Cancer Institute, Inc. (US) | 2019-09-11 | — | — | EP | disclosed |
| US-10265321-B2 | Uses of salt-inducible kinase (SIK) inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180221379-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-08-09 | — | — | US | disclosed |
| US-20180221379-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-08-09 | — | — | US | disclosed |
| US-20170224700-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170224700-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| WO-2016023014-A2 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190343842-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | SIK1, SIK3, SIK2 | LCK 215/4885FGFR3 1863/4885FGFR1 2142/4885 |
| US-20200179387-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS | SOST, SIK2, SIK1 | LCK 308/4885FGFR3 710/4885FGFR1 854/4885 |
| US-20220305016-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS FOR TREATING OSTEOPOROSIS | SOST, SIK2, SIK1 | LCK 308/4885FGFR3 710/4885FGFR1 854/4885 |
| US-10265321-B2 | Uses of salt-inducible kinase (SIK) inhibitors | SIK1, SIK2, SIK3 | LCK 239/4885FGFR3 1974/4885FGFR1 2176/4885 |
| US-20170224700-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | SIK1, SIK2, SIK3 | LCK 239/4885FGFR3 1974/4885FGFR1 2176/4885 |
| US-11241435-B2 | Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosis | SOST, SIK2, SIK1 | LCK 308/4885FGFR3 710/4885FGFR1 854/4885 |
| US-20200338087-A9 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | SIK1, SIK3, SIK2 | LCK 215/4885FGFR3 1863/4885FGFR1 2142/4885 |
| US-20180221379-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | SIK1, SIK2, SIK3 | LCK 239/4885FGFR3 1974/4885FGFR1 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.